(Q37976135)

26 August 2017

title

Pharmacokinetic evaluation of axitinib (English)

1 reference

26 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Brian Patson

1

1 reference

26 August 2017

Roger B Cohen

series ordinal

2

1 reference

26 August 2017

Anthony J Olszanski

series ordinal

3

1 reference

26 August 2017

language of work or name

English

0 references

publication date

17 January 2012

1 reference

Expert Opinion on Drug Metabolism & Toxicology

26 August 2017

published in

1 reference

26 August 2017

volume

8

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

259-270

1 reference

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

MR imaging of tumor microcirculation: promise for the new millennium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2012.652947

10.1517/17425255.2012.652947

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference